Insights
Idiosyncratic drug-induced liver and kidney injury
Domain entry for idiosyncratic drug-induced liver injury (DILI): published work used the CC multi-strain panel (45 strains) to study tolvaptan-induced liver injury susceptibility and biomarkers; ADPKD is only the clinical context of the drug, and no kidney-injury model evidence is cited for this entry.
Domain entry for idiosyncratic drug-induced liver injury (DILI): published work used the CC multi-strain panel (45 strains) to study tolvaptan-induced liver injury susceptibility and biomarkers; ADPKD is only the clinical context of the drug, and no kidney-injury model evidence is cited for this entry.
Research uses
Strain/individual variability in idiosyncratic DILI susceptibility; mechanisms of DILI (bile acid homeostasis, oxidative stress, mitochondrial dysfunction, innate immune response); serum susceptibility biomarker (Slpi).